Evidence map›Paper›PMID 29162878›Full record

ArticleScientific reports2017

Comparative analysis of cytokine/chemokine regulatory networks in patients with hippocampal sclerosis (HS) and focal cortical dysplasia (FCD).

Arpna Srivastava, Aparna Banerjee Dixit, Debasmita Paul, Manjari Tripathi, Chitra Sarkar, P Sarat Chandra, Jyotirmoy Banerjee

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Arpna SrivastavaCentre of Excellence for Epilepsy, a joint collaboration of NBRC & AIIMS, New Delhi, India.
Aparna Banerjee DixitCentre of Excellence for Epilepsy, a joint collaboration of NBRC & AIIMS, New Delhi, India.
Debasmita PaulCentre of Excellence for Epilepsy, a joint collaboration of NBRC & AIIMS, New Delhi, India.
Manjari TripathiCentre of Excellence for Epilepsy, a joint collaboration of NBRC & AIIMS, New Delhi, India.
Chitra SarkarDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
P Sarat ChandraCentre of Excellence for Epilepsy, a joint collaboration of NBRC & AIIMS, New Delhi, India.
Jyotirmoy BanerjeeCentre of Excellence for Epilepsy, a joint collaboration of NBRC & AIIMS, New Delhi, India. jyotirmoybanerjee1@gmail.com.
All India Institute of Medical Sciences Bhopal · INAll India Institute of Medical Sciences Raipur · INAll India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Experimental and clinical evidence have demonstrated aberrant expression of cytokines/chemokines and their receptors in patients with hippocampal sclerosis (HS) and focal cortical dysplasia (FCD). However, there is limited information regarding the modulation of cytokine/chemokine-regulatory networks, suggesting contribution of miRNAs and downstream transcription factors/receptors in these pathologies. Hence, we studied the levels of multiple inflammatory mediators (IL1β, IL1Ra, IL6, IL10, CCL3, CCL4, TNFα and VEGF) along with transcriptional changes of nine related miRNAs and mRNA levels of downstream effectors of significantly altered cytokines/chemokines in brain tissues obtained from patients with HS (n = 26) and FCD (n = 26). Up regulation of IL1β, IL6, CCL3, CCL4, STAT-3, C-JUN and CCR5, and down regulation of IL 10 were observed in both HS and FCD cases (p < 0.05). CCR5 was significantly up regulated in FCD as compared to HS (p < 0.001). Both, HS and FCD presented decreased miR-223-3p, miR-21-5p, miR-204-5p and let-7a-5p and increased miR-155-5p expression (p < 0.05). As compared to HS, miR-204-5p (upstream to CCR5 and IL1β) and miR-195-5p (upstream to CCL4) were significantly decreased in FCD patients (p < 0.01). Our results suggest differential alteration of cytokine/chemokine regulatory networks in HS and FCD and provide a rationale for developing pathology specific therapy.

Indexed as

Gene Regulatory NetworksAdolescentAdultCase-Control StudiesChemokinesChildEpilepsyFemaleGene Expression ProfilingHippocampusHumansInflammationInflammation MediatorsMaleMalformations of Cortical DevelopmentMicroRNAsChemokinesInflammation MediatorsMicroRNAsRNA, Messenger

Identifiers

PMID29162878
PMCPMC5698416
OpenAlexW2770049589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.